Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: Is there something here?

John Aucott, Alison W. Rebman, Lauren A. Crowder, Kathleen Bechtold Kortte

Research output: Contribution to journalArticle

Abstract

Purpose: A subset of patients treated for Lyme disease report persistent or recurrent symptoms of unknown etiology named post-treatment Lyme disease syndrome (PTLDS). This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-treatment symptomatology and functional impact of PTLDS over time. Methods: Sixty-three participants with erythema migrans and systemic symptoms were enrolled in a prospective cohort study. Participants underwent physical exams and clinical assessments, and completed the SF-36 (daily life functioning) and the Beck Depression Inventory, Second Edition (BDI-II) (depression), at each of five visits over a period of 6 months. Results: Signs of Lyme disease disappeared post-treatment; however, new-onset patient-reported symptoms increased or plateaued over time. At 6 months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties. However, less than 10% reported greater than "minimal" depression across the entire period. Those with PTLDS (36%) did not differ significantly from those without with respect to demographics, pre-treatment SF-36, and BDI-II scores. Statistically significant differences were found over time on the Role Physical, Vitality, Social Functioning, Role Emotional, and Mental Health subscales (with a trend toward significance for the remaining three subscales of Physical Functioning, Bodily Pain, and General Health) of the SF-36 between those with an eventual PTLDS diagnosis and those without when measured at 6 months. Conclusions: Unlike clinical signs of Lyme disease, new-onset symptoms are reported by a subset of participants without evidence of depressive symptomatology. Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS. We propose future avenues for researching infection-triggered symptoms resulting from multiple mechanisms.

Original languageEnglish (US)
Pages (from-to)75-84
Number of pages10
JournalQuality of Life Research
Volume22
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Lyme Disease
Therapeutics
Depression
Pain
Erythema
Fatigue
Mental Health
Cohort Studies
Demography
Prospective Studies
Equipment and Supplies

Keywords

  • Chronic disease
  • Depression
  • Life functioning
  • Outcomes
  • Post-treatment Lyme disease syndrome

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Cite this

Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning : Is there something here? / Aucott, John; Rebman, Alison W.; Crowder, Lauren A.; Kortte, Kathleen Bechtold.

In: Quality of Life Research, Vol. 22, No. 1, 02.2013, p. 75-84.

Research output: Contribution to journalArticle

@article{b851a8ef8393447eb6386796c4f4d975,
title = "Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: Is there something here?",
abstract = "Purpose: A subset of patients treated for Lyme disease report persistent or recurrent symptoms of unknown etiology named post-treatment Lyme disease syndrome (PTLDS). This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-treatment symptomatology and functional impact of PTLDS over time. Methods: Sixty-three participants with erythema migrans and systemic symptoms were enrolled in a prospective cohort study. Participants underwent physical exams and clinical assessments, and completed the SF-36 (daily life functioning) and the Beck Depression Inventory, Second Edition (BDI-II) (depression), at each of five visits over a period of 6 months. Results: Signs of Lyme disease disappeared post-treatment; however, new-onset patient-reported symptoms increased or plateaued over time. At 6 months, 36{\%} of patients reported new-onset fatigue, 20{\%} widespread pain, and 45{\%} neurocognitive difficulties. However, less than 10{\%} reported greater than {"}minimal{"} depression across the entire period. Those with PTLDS (36{\%}) did not differ significantly from those without with respect to demographics, pre-treatment SF-36, and BDI-II scores. Statistically significant differences were found over time on the Role Physical, Vitality, Social Functioning, Role Emotional, and Mental Health subscales (with a trend toward significance for the remaining three subscales of Physical Functioning, Bodily Pain, and General Health) of the SF-36 between those with an eventual PTLDS diagnosis and those without when measured at 6 months. Conclusions: Unlike clinical signs of Lyme disease, new-onset symptoms are reported by a subset of participants without evidence of depressive symptomatology. Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS. We propose future avenues for researching infection-triggered symptoms resulting from multiple mechanisms.",
keywords = "Chronic disease, Depression, Life functioning, Outcomes, Post-treatment Lyme disease syndrome",
author = "John Aucott and Rebman, {Alison W.} and Crowder, {Lauren A.} and Kortte, {Kathleen Bechtold}",
year = "2013",
month = "2",
doi = "10.1007/s11136-012-0126-6",
language = "English (US)",
volume = "22",
pages = "75--84",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning

T2 - Is there something here?

AU - Aucott, John

AU - Rebman, Alison W.

AU - Crowder, Lauren A.

AU - Kortte, Kathleen Bechtold

PY - 2013/2

Y1 - 2013/2

N2 - Purpose: A subset of patients treated for Lyme disease report persistent or recurrent symptoms of unknown etiology named post-treatment Lyme disease syndrome (PTLDS). This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-treatment symptomatology and functional impact of PTLDS over time. Methods: Sixty-three participants with erythema migrans and systemic symptoms were enrolled in a prospective cohort study. Participants underwent physical exams and clinical assessments, and completed the SF-36 (daily life functioning) and the Beck Depression Inventory, Second Edition (BDI-II) (depression), at each of five visits over a period of 6 months. Results: Signs of Lyme disease disappeared post-treatment; however, new-onset patient-reported symptoms increased or plateaued over time. At 6 months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties. However, less than 10% reported greater than "minimal" depression across the entire period. Those with PTLDS (36%) did not differ significantly from those without with respect to demographics, pre-treatment SF-36, and BDI-II scores. Statistically significant differences were found over time on the Role Physical, Vitality, Social Functioning, Role Emotional, and Mental Health subscales (with a trend toward significance for the remaining three subscales of Physical Functioning, Bodily Pain, and General Health) of the SF-36 between those with an eventual PTLDS diagnosis and those without when measured at 6 months. Conclusions: Unlike clinical signs of Lyme disease, new-onset symptoms are reported by a subset of participants without evidence of depressive symptomatology. Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS. We propose future avenues for researching infection-triggered symptoms resulting from multiple mechanisms.

AB - Purpose: A subset of patients treated for Lyme disease report persistent or recurrent symptoms of unknown etiology named post-treatment Lyme disease syndrome (PTLDS). This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-treatment symptomatology and functional impact of PTLDS over time. Methods: Sixty-three participants with erythema migrans and systemic symptoms were enrolled in a prospective cohort study. Participants underwent physical exams and clinical assessments, and completed the SF-36 (daily life functioning) and the Beck Depression Inventory, Second Edition (BDI-II) (depression), at each of five visits over a period of 6 months. Results: Signs of Lyme disease disappeared post-treatment; however, new-onset patient-reported symptoms increased or plateaued over time. At 6 months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties. However, less than 10% reported greater than "minimal" depression across the entire period. Those with PTLDS (36%) did not differ significantly from those without with respect to demographics, pre-treatment SF-36, and BDI-II scores. Statistically significant differences were found over time on the Role Physical, Vitality, Social Functioning, Role Emotional, and Mental Health subscales (with a trend toward significance for the remaining three subscales of Physical Functioning, Bodily Pain, and General Health) of the SF-36 between those with an eventual PTLDS diagnosis and those without when measured at 6 months. Conclusions: Unlike clinical signs of Lyme disease, new-onset symptoms are reported by a subset of participants without evidence of depressive symptomatology. Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS. We propose future avenues for researching infection-triggered symptoms resulting from multiple mechanisms.

KW - Chronic disease

KW - Depression

KW - Life functioning

KW - Outcomes

KW - Post-treatment Lyme disease syndrome

UR - http://www.scopus.com/inward/record.url?scp=84872678519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872678519&partnerID=8YFLogxK

U2 - 10.1007/s11136-012-0126-6

DO - 10.1007/s11136-012-0126-6

M3 - Article

C2 - 22294245

AN - SCOPUS:84872678519

VL - 22

SP - 75

EP - 84

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 1

ER -